Looking for leads, investment insights, or competitive intelligence?
News about Roche Group
But Shionogi's Xofluza likely won't be available in the U.S. till at least 2019.
Flatiron is connected with hundreds of cancer treatment centers—and its data collection could spur new drugs.
Roche would pay $27 per share for Ignyta.
The finding could result in annual sales of $4.6 billion by 2023.
The FDA approved the first cancer medicine "biosimilar" Thursday.